Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
HCPC | J9269 |
Short Description | Inj. tagraxofusp-erzs 10 mcg |
Long Description | Injection, tagraxofusp-erzs, 10 micrograms |
Pricing indicator | 51 |
Coverage code | C |
ASC payment group code | YY |
BETOS2 code | O1D |
Action code | N |
Type of service | 1 |
Effective date | 2019-10-01 |
Date Added | 2019-10-01 |
HCPCS/NDC Cross-Walk
NDC | HCPC | Description | Drug Name | Labeler Name | HCPCS Dosage | PKG Size | PKG QTY | Bill Units | Bill Units PKG |
---|---|---|---|---|---|---|---|---|---|
72187040101 | J9269 | Inj. tagraxofusp-erzs 10 mcg | Elzonris | STEMLINE THERAPEUTICS | 10 MCG | 1 | 1 | 100 | 100 |
HCPCS Billing Calculator
Dosage given to patient (per dose) | |
---|---|
HCPCS Dosage | 10 MCG |
HCPCS/CPT Billing Units | 0.1 |
Total doses ordered | |
Billing Units | 0.1 |
Drug Details
-
Tagraxofusp-erzs injection is used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN; a blood cancer that causes skin lesions, and may spread to the bone marrow and lymphatic system) in adults and children 2 years of age and older. Tagraxofusp-erzs is in a class of medications called CD123 cytotoxin. It works by killing cancer cells.